MilliporeSigma Becomes the First to Use Acoustic Technology for Cell Therapy Manufacturing
MilliporeSigma recently announced it has acquired FloDesign Sonics, of Wilbraham, MA, developer of a unique acoustic cell processing platform for the industrialization of cell and gene therapy manufacturing. Financial details were not disclosed.
“Chimeric antigen receptor T cell therapies, or CAR-T for short, employs the body’s own immune systems to fight cancer by turning T cells into targeted therapeutics. This revolutionary cancer treatment is challenging and complex, with the process often taking up to a month,” said Udit Batra, CEO, MilliporeSigma. “Our acquisition of FloDesign Sonic will industrialize the manufacturing of autologous cell therapy, allowing these types of potentially life-saving treatments to reach more patients, faster.”
MilliporeSigma is the first company to make acoustic technology available for cell therapy manufacturing. Acoustic cell processing is a disruptive technology that allows for the manipulation of cells with ultrasonic waves. FloDesign Sonics’ acoustic cell processing platform allows enhanced cell washing and concentration for manufacturing cell therapies. The acquisition is a strategic fit for MilliporeSigma, strengthening the ability to advance cell-based therapies to patients.
“MilliporeSigma is the best home for FloDesign Sonics, our acoustic cell processing technology and our employees,” said Stanley Kowalski III, Co-founder, Chairman and CEO of FloDesign Sonics. “The opportunity for FloDesign Sonics to become part of a world class 351-year-old science and technology company is very rewarding.”
Founded in 2009, the company develops an acoustic cell processing platform for cell and gene therapy applications. FDS just recently (Q1 2019) launched its first commercial product (Ekko) which allows the wash, concentration and formulation within Autologous CAR-T Manufacturing workflow. For more information, visit www.fdsonics.com/technology.
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 21,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany generated sales of €14.8 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.
Total Page Views: 336